Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P

被引:88
|
作者
Koopman, Karen [3 ,6 ]
Le Bastard, Nathalie [1 ]
Martin, Jean Jacques [2 ]
Nagels, Guy [3 ,7 ]
De Deyn, Peter P. [1 ,2 ,3 ,5 ]
Engelborghs, Sebastiaan [1 ,3 ,4 ,5 ]
机构
[1] Univ Antwerp, Lab Neurochem & Behav, Inst Born Bunge, Reference Ctr Biol Markers Memory Disorders, BE-2610 Antwerp, Belgium
[2] Univ Antwerp, Biobank, Inst Born Bunge, BE-2610 Antwerp, Belgium
[3] Middelheim Gen Hosp ZNA, Dept Neurol & Memory Clin, Antwerp, Belgium
[4] Univ Antwerp, Dept Nursing Sci, Fac Med, BE-2610 Antwerp, Belgium
[5] Univ Coll Antwerp, Dept Hlth Care Sci, Merksem, Belgium
[6] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9713 AV Groningen, Netherlands
[7] Natl Multiple Sclerosis Ctr, Melsbroek, Belgium
关键词
Dementia; Alzheimer's disease; Cerebrospinal fluid; Biomarkers; Hyperphosphorylated tau; MILD COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID; PHOSPHORYLATED-TAU; CLINICAL-DIAGNOSIS; BIOMARKERS; MARKERS; PERFORMANCE;
D O I
10.1016/j.neuint.2009.02.017
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
To establish diagnostic accuracy (acc) and optimal cut-off levels of CSF tau phosphorylated at threonine 181 (P-tau(181P)) for discriminating Alzheimer's disease (AD) from non-AD dementias in autopsy-confirmed dementia patients, CSF levels of beta-amyloid peptide (A beta(1-42)). total tau protein (T-tau) and P-tau(181P) from patients with definite AD (n=95) and non-AD demential (n=50) were determined with single-parameter ELISA kits. Optimal P-tau(181P) cut-off levels for differentiating AD from pooled non-AD demential, dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD) were 50.4 pg/mL (acc = 0.73), 52.8 pg/mL (acc = 0.73) and 35.3 pg/mL (acc = 0.90), respectively. The optimal CSF P-tau(181P) cut-off level for discriminating AD from non-AD demential was 50.4 pg/mL. Optimal CSF P-tau(181P) cut-off levels differed between non-AD diagnostic dementia categories. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:214 / 218
页数:5
相关论文
共 50 条
  • [1] Ratio of Aβ42/P-tau181p in CSF is associated with aberrant default mode network in AD
    Xiaozhen Li
    Tie-Qiang Li
    Niels Andreasen
    Maria Kristoffersen Wiberg
    Eric Westman
    Lars-Olof Wahlund
    Scientific Reports, 3
  • [2] Ratio of Aβ42/P-tau181p in CSF is associated with aberrant default mode network in AD
    Li, Xiaozhen
    Li, Tie-Qiang
    Andreasen, Niels
    Wiberg, Maria Kristoffersen
    Westman, Eric
    Wahlund, Lars-Olof
    SCIENTIFIC REPORTS, 2013, 3
  • [3] Validation of the AD-CSF-Index in Autopsy-Confirmed Alzheimer's Disease Patients and Healthy Controls
    Struyfs, Hanne
    Molinuevo, Jose L.
    Martin, Jean-Jacques
    De Deyn, Peter Paul
    Engelborghs, Sebastiaan
    JOURNAL OF ALZHEIMERS DISEASE, 2014, 41 (03) : 903 - 909
  • [4] Amyloid beta (Aβ) immunoreactivity in the retina of Alzheimer's disease (AD) and non-AD dementias: A pilot study
    Matsubara, Joanne A.
    Hirsch-Reinshagen, Veronica
    Mackenzie, Ian R.
    Hsiung, Robin Ging-Yuek
    Eadie, Brennan
    Lee, Sieun
    Jiang, Kailun
    Sarunic, Marinko Venci
    Beg, Mirza Faisal
    Cui, Jing Z.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [5] Resting-state fMRI distinguishes Alzheimer's disease from non-AD dementias
    Greicius, M
    Seeley, WW
    Miller, BL
    Parthasarathy, S
    Reiss, AL
    Menon, V
    NEUROLOGY, 2006, 66 (05) : A104 - A104
  • [6] Antemortem CSF Tau and Aβ Biomarkers Are Predictive of Postmortem Alzheimer's Disease Pathology in Autopsy-Confirmed Lewy Body Disease
    Irwin, David J.
    Coughlin, David
    Nevler, Naomi
    Akhtar, Rizwan S.
    McMillan, Corey T.
    Lee, Edward B.
    Wolk, David
    Weintraub, Daniel
    Shaw, Leslie M.
    Grossman, Murray
    Trojanowski, John Q.
    ANNALS OF NEUROLOGY, 2017, 82 : S56 - S56
  • [7] The effects of non-modifiable risk factors of Alzheimer's disease (AD) on concentrations of plasma P-tau181 in clinically diagnosed AD
    Hsiung, Ging-Yuek R.
    Kumar, Pankaj
    Mousavi, Ali
    Encarnacion, Mary
    Frykman, Hans
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [8] Levels of plasma brain-derived tau and p-tau181 in Alzheimer's disease and rapidly progressive dementias
    Gonzalez-Ortiz, Fernando
    Karikari, Thomas K.
    Bentivenga, Giuseppe Mario
    Baiardi, Simone
    Mammana, Angela
    Turton, Michael
    Kac, Przemyslaw R.
    Mastrangelo, Andrea
    Harrison, Peter
    Capellari, Sabina
    Zetterberg, Henrik
    Blennow, Kaj
    Parchi, Piero
    ALZHEIMERS & DEMENTIA, 2024, 20 (01) : 745 - 751
  • [9] Does CSF p-tau181 help to discriminate Alzheimer's disease from other dementias and mild cognitive impairment? A meta-analysis of the literature
    Tang, Wei
    Huang, Qiong
    Yao, Yu-You
    Wang, Yan
    Wu, Yi-Le
    Wang, Zheng-Yu
    JOURNAL OF NEURAL TRANSMISSION, 2014, 121 (12) : 1541 - 1553
  • [10] Does CSF p-tau181 help to discriminate Alzheimer’s disease from other dementias and mild cognitive impairment? A meta-analysis of the literature
    Wei Tang
    Qiong Huang
    Yu-You Yao
    Yan Wang
    Yi-Le Wu
    Zheng-Yu Wang
    Journal of Neural Transmission, 2014, 121 : 1541 - 1553